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Cardiac Function and Heart Failure
Endothelial function of the coronary microcirculation is impaired in patients with myocar-
dial virus persistence. Endothelial dysfunction is more pronounced with concurrent myo-
cardial inflammation, but can be demonstrated in patients without myocardial
inflammation. We conclude that there is a direct interaction between myocardial virus
persistence and endothelial dysfunction.
1164-129 The Pediatric Expression of Isolated Ventricular 
Noncompaction: Clinical Characteristics, Prognosis, 
and Outcome
Rachel M. Wald, Gruschen R. Veldtman, Brian W. McCrindle, Joel A. Kirsh, Lee N. 
Benson, Hospital for Sick Children, Toronto, ON, Canada
Background: Isolated ventricular noncompaction (IVNC) is a rare form of cardiomyopa-
thy with a broad clinical spectrum that is not well defined in the pediatric population.With
improvements in imaging modalities, IVNC has emerged as an under-recognized and
important cause of pediatric cardiomyopathy. This review focuses on the clinical charac-
teristics and prognosis of IVNC and evaluates the potential determinants of outcome.
Methods: Echocardiograms were analyzed to confirm diagnosis and to measure non-
compacted:compacted segment ratio, left ventricle (LV) size, ejection fraction (EF), and
Tei index, both at presentation and at most recent visit. Medical records, electrocardio-
grams, Holter recordings and heart rate variability (HRV) data were also reviewed. 
Results: Twenty-two consecutive patients (9 male), mean age 3.86 years at diagnosis
(range birth-16 years), were studied. Heart failure (n=13) and/or arrhythmias (supraven-
tricular n=1, and ventricular n=2) were commonly seen at presentation. Initial echocardio-
graphy demonstrated systolic dysfunction in 17/22 patients (median LVEF 34%, range 6-
67%). During a median follow-up of 2.98 years (range 0.07-15.7 years), medical therapy
was instituted in 20 patients. Ten received beta-blockade in addition to a combination of
digoxin, diuretics and angiotensin converting enzyme inhibitors. Four patients demon-
strated marked response to medical therapy (median EF at presentation 17%, median
EF at last follow-up 45%, duration of therapy range 19-37 months). Overall, stabilization
or improvement was noted in 70% (n=7/10) on beta-blockade. Poor outcome, defined as
transplantation or transplant listing (n=3) or death (n=3) occurred in 27%. Predictors of
listing for transplant and/or death were increased noncompaction:compaction segment
ratio at diagnosis (p=0.01) and increased left ventricular end diastolic dimension (LVED)
at presentation (p=0.05).
Conclusions: IVNC is associated with poor outcome in 27%, which may be predicted by
increased noncompacted segment ratio and/or LVED at presentation. With medical ther-
apy, notably beta-blockade, many can achieve hemodynamic stability or even improved
ventricular function.
1164-130 Chronotropic Stress Enhances the Effects of 
Asynchronous Left Ventricular Activation on Myocardial 
Perfusion in Patients With Idiopathic Dilated 
Cardiomyopathy and Left Bundle Branch Block
Cecilia Marini, Jan Schneider-Eicke, Piero Salvadori, Gianmario Sambuceti, Antonio 
L'Abbate, Danilo Neglia, CNR Institute of Clinical Physiology, Pisa, Italy
Asynchronous left ventricular (LV) activation due to left bundle branch block (LBBB) may
worsen LV function in patients with idiopathic dilated cardiomyopathy (IDC). Aim of this
study was to assess whether this mechanism is enhanced by chronotropic stress and
may affect myocardial blood flow (MBF). To this purpose 17 patients with IDC (NYHA
class I-II, LVEF 36±9%), 9 with and 8 without LBBB, were studied together with 5 normal
subjects. Global and regional MBF values in the septum (S) and in the postero-lateral
wall (PL) were quantitated (ml/min/g) by 13NH3 and positron emission tomography at
rest and during maximal atrial pacing (131±12 bpm). Global and regional EF values at
rest and during pacing were also obtained by equilibrium radionuclide angiography in a
one day protocol. Changes in EF and MBF during stress are presented as stress/rest
ratios. At rest, as compared with normals, patients with and without LBBB had similarly
depressed global LV EF (32±8% and 41±8% vs 58±5%, p<0.001) and comparable global
MBF (0.90±0.22 and 0.78±0.26 vs 0.91±0.17 ml/min/g, ns). During pacing, the regional
EF in S significantly decreased in the LBBB group as compared with normals (0.38±0.36
vs 1.08±0.05, p<0.05) while changes in global EF and regional EF in PL did not signifi-
cantly differ among groups. Global and regional MBF in S increased significantly less
during pacing in patients with LBBB than in normals (1.30±0.22 vs 1.81±0.33 and
1.26±0.21 vs 1.81±0.44, p<0.05) while the regional MBF changes in PL did not differ
between IDC groups.
In conclusion, in patients with IDC and LBBB chronotropic stress enhances the effects of
asynchronous LV activation causing a limitation of regional and global myocardial flow
reserve.
1164-131 Clinical Significance of Lamin A/C Mutations in Dilated 
Cardiomyopathy
Anita M. Arola, Hua Li, Ross Murphy, William J. McKenna, Neil E. Bowles, Jeffrey A. 
Towbin, Baylor College of Medicine, Houston, TX, St. George's Hospital Medical School, 
London, United Kingdom
Background: Dilated cardiomyopathy (DCM), characterized by ventricular dilation and
decreased systolic function, is estimated to be of genetic origin in over 30% of cases. To
date, mutations in 12 different genes, mainly encoding cytoskeletal and sarcomeric pro-
teins, have been associated with familial and sporadic forms of DCM. Mutations in the
gene encoding nuclear envelope protein lamin A/C (LMNA) have been reported in up to
33% of patients with familial DCM, frequently associated with conduction system disease
and variable skeletal muscle involvement. In this study, we evaluated the frequency of
laminopathies in an unselected patient population with DCM.
Methods: LMNA and emerin (EMD) genes were amplified by PCR from the genomic
DNA of 185 unrelated DCM patients and analyzed by denaturing high-performance liquid
chromatography (DHPLC) and sequenced using a Big-Dye Terminator cycle sequencing
system. Institutional review boards approved the study, and all the study subjects gave
their written informed consent.
Results: Three novel mutations in LMNA were identified including a missense mutation
(E291K) in exon 5, a splice site mutation (356+1 G→C) after exon 1, and an insertion
(751insC) in exon 4. Moreover, two previously reported missense mutations (Y45C,
R190W) were found. The phenotype of the patients with LMNA mutations ranged from
pure sporadic DCM without conduction system disease to autosomal dominant DCM with
complete atrio-ventricular block but no signs or symptoms of skeletal muscle disease.
Analysis of EMD identified only one silent mutation.
Conclusions: Potential disease-causing mutations in LMNA were found in only 5 out of
185 (2.7%) patients with DCM. Functional studies to evaluate the significance of these
mutations are ongoing. Genetic defects in EMD do not seem to have a significant role in
the pathogenesis of DCM. In conclusion, defects in LMNA are not common in unselected
patients with DCM, but need to be screened in both pure DCM and DCM with conduction
system disease.
1164-132 Effect of Acute Administration of L-Propionylcarnitine 
on Coronary Flow Velocity Reserve in Patients With 
Systemic Sclerosis
Roberta Montisci, Massimo Ruscazio, Alessandra Vacca, Pietro Garau, Giuseppe 
Passiu, Alessandro Mathieu, Sabino Iliceto, Luigi Meloni, University of Cagliari, Cagliari, 
Italy
Background. Cardiac involvement in systemic sclerosis ( SSc) is controversial but the
primary disorder of microvasculature with diffuse arteriolar and capillary lesions could
precede any fibrosis, thus causing ischemic dysfunction. Previous studies of coronary
flow velocity reserve (CFVR) have demonstrated that CFVR is impaired in patients with
SSc. L-Propionylcarnitine( L-Pc) is a metabolic substance that exerts a beneficial effect
on both microcirculation and myocite function. We tested the hypothesis that CFVR can
be early impaired in patients with SSc without cardiac involvement and whether CFVR
could improve after intravenous administration of L-Pc.
Methods. We studied 11 females patients (6 with diffuse form and 5 with localized form
of SSc) without clinical evidence of heart disease, mean age 54±11 years and 26 control
group patients, matched for age. We evaluated CFVR in the left anterior descending cor-
onary artery (LAD) with contrast Doppler echocardiography during adenosine infusion
(140 µg/Kg/min in 5 minutes), before and after 15 minutes of administration of L-Pc ( 300
mg intravenous in 5 minutes bolus) .
Results: In patients with SSc CFVR was impaired in comparison to the control group
patients ( 2.56 ± 0.54 vs 3.29±0.52, p=0.0005). Furthermore, in patients with SSc after
administration of L-Pc, CFVR increased from 2.56 ± 0.51 to 3.38±0.9, p=0.01. The peak
diastolic velocity in the LAD at rest, before and after L-Pc administration were not differ-
ent (33.8 ±11 vs 28.5±8.6, p=ns).
Conclusion. CFVR is early impaired in patients with SSc without clinical evidence of
heart disease. Acute administration of L-Pc exerts a beneficial effect on microvasculature
in patients with systemic sclerosis. Therefore, its potential after chronic administration
needs to be evaluated.
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1165-103 Effect of Beta-Blocker Therapy on Ventilatory 
Responses in Patients With Heart Failure
Robert Wolk, Bruce D. Johnson, Virend K. Somers, Thomas G. Allison, Ray W. Squires, 
Gerald T. Gau, Lyle J. Olson, Mayo Clinic, Rochester, MN
Background. An augmented ventilatory response to exercise is frequently observed in
patients (pts) with congestive heart failure (CHF). Beta-blocker therapy of CHF improves
hemodynamics, survival and symptoms though it does not improve peak oxygen uptake
(VO2). We hypothesized beta-blocker therapy decreases minute ventilation (VE) in pts
with CHF. Methods. The study group was comprised of 629 CHF pts with LVEF <40%
referred for cardiopulmonary exercise testing (CPET) from 1994 to 2002. Clinical,
echocardiographic, pulmonary function (PFT) and CPET data were reviewed and
recorded. Pts were divided into two subgroups for comparison: those treated with beta-
blockers (n=206) and those not treated with beta-blockers (n=423). Results. Gender,
smoking history, etiology of CHF, other cardioactive medications and PFT findings were
not different for the two subgroups. LVEF was slightly higher (25 vs. 23; p=0.01) with
beta-blocker. At rest, CHF pts on beta-blocker had significantly lower VE (12±4 vs. 14±4
l/min, p<0.001) and increased ventilatory efficiency (42±7 vs. 44±8, p<0.001). VE
remained lower in the beta-blocker subgroup during submaximal and maximal exercise,
by 4 and 6 l/min, respectively (p=0.001). Expired carbon dioxide was not different
between the two subgroups at rest, submaximal or maximal exercise. Ventilatory effi-
ciency was significantly improved at submaximal (32±6 vs. 34±7, p=0.005) and maximal
(34±8 vs. 36±10, p=0.006) exercise with beta-blocker treatment. Peak VO2 was not sig-
nificantly different for the two subgroups (19.1±5.7 vs. 18.6±5.6), though exercise dura-
tion was significantly longer (7.0 vs. 6.5 min; p=0.018) with beta blocker. The differences
in VE and ventilatory efficiency between the two subgroups remained significant by cova-
riate analysis when age, gender, LVEF, peak VO2, body mass index, CHF etiology, smok-
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ing history, and medications were considered. Beta-blocker therapy was also
independently associated with decreased VE by multiple regression analysis. Conclu-
sion. Beta-blocker therapy decreases VE and increases ventilatory efficiency at rest and
during exercise in CHF pts which may contribute to improved functional class and quality
of life.
1165-104 Somatosensory Stimulation as an Alternative for 
Exercise to Enhance the Arterial Baroreflex
Cees A. Swenne, Yiping Sun, Liming Han, Martin J. Schalij, Henk J. Van Exel, Caroline M 
H B Lucas, Arie C. Maan, Harriette F. Verwey, Hedde Van de Vooren, Ernst E. Van der 
Wall, Leiden University Medical Center, Leiden, The Netherlands
Background. Arterial baroreflex sensitivity has important prognostic value in cardiovas-
cular disease. Patients should exercise because baroreflex sensitivity decreases with
physical inactivity, however, disease oftentimes seriously reduces exercise tolerance.
Here, we demonstrate that exercise-mimicking somatosensory stimulation alone, hence
without any actual exercise, is sufficient for arterial baroreflex improvement.
Methods. Before-after intervention trial conducted in the Leiden University Medical Cen-
ter between September 2001 and July 2002 in 21 (15 male and 6 female) randomly
selected outpatients with stable chronic heart failure (mean ± SD age 61.2 ± 11.4 years,
New York Heart Association heart failure class 2.1 ± 0.7). Intervention consisted of one
hour of somatosensory stimulation (by transcutaneous electrical nerve stimulation), at
walking pace, of nerves conducting ergoreceptor information from the feet. Core ses-
sions (control-, intermediate-, effect-) of the study were held at three consecutive days.
Rehearsal- and residue-effect sessions were held one week before and one week after
the core sessions, respectively. Somatosensory stimulation was applied during the
rehearsal-, control-, and intermediate sessions.
Results. Baroreflex sensitivity (reflex increase of the interval between heart beats per
mmHg systolic blood pressure rise) increased (P=0.016) by 57% from 3.57 ± 1.98 (con-
trol session) to 5.60 ± 2.79 (effect session) ms/mmHg. Baroreflex sensitivity in the resi-
due session did not differ significantly from the control session value.
Conclusions. In chronic heart failure patients, the arterial baroreflex can readily be
enhanced by exercise-mimicking somatosensory stimulation without any muscular
involvement. This finding supports the concept that exercise-associated sensations alone
- hence, apart from any actual exercise - are able to bring about training effects in the
autonomic nervous system, in congestive heart failure, but possibly also in other patient
groups. Follow-up studies should be done to establish the concrete health benefits of
somatosensory stimulation for those who cannot exercise.
1165-105 Exercise Training Reduces Vascular Inflammation in 
Patients With Cardiovascular Risk or Disease
Alexander Niessner, Bernhard Richter, Martina Penka, Sabine Steiner, Barbara Strasser, 
Sophie Ziegler, Elke Heeb-Elze, Gerlinde Zorn, Angelika Leitner-Heinschink, Johann 
Wojta, Kurt Huber, University of Vienna, Vienna, Austria
Background: The aim of our study was to investigate if reduced cardiovascular risk due
to endurance training is partly mediated by decreased vascular inflammation.
Methods: We studied 32 humans (f/m: 19:13, 31-58 yrs) with elevated cardiovascular
risk (CVR: n = 22, cholesterol > 200 mg/dl: 68%, DM: 59%, hypertension: 27%, BMI > 30:
18%, smoker: 9%) or proven coronary heart disease (CHD: n = 10, CCS < II). They par-
ticipated in a controlled training (endurance running) of 12 weeks (3-4 hrs/w). Circulating
IL-6, high sensitivity C-reactive protein (hsCRP), soluble CD40 ligand (sCD40L), mono-
cyte chemotactic protein 1 (MCP-1), and IL-8 were determined before (B) and after (A)
the training (after 48 hrs of rest) by immunoassays. In addition, we compared A values to
sedentary controls (C) matched for age, sex and disease. We decided to use parametric
(P: mean + SD, paired T-Test) or nonparametric analysis (NP: median [25th, 75th percen-
tile], Wilcoxon Signed Ranks Test) based on the Kolmogorov-Smirnov Test.
Results: The effect of training was confirmed by a 13.7 % mean decrease of time for a 2
km test-run with the individual training`s heart rate. MCP-1 (P: 213 + 50 vs 193 + 65.6 pg/
ml, p = .034) and IL-8 (NP: 88.5 [13.4, 1177] vs 42.5 [17.2, 968] pg/ml, p = .043) but not
IL-6 (p = .26), hsCRP (p = .67), and sCD40L (p = .11) decreased in response to training.
However, IL-6 (NP: 4 [2.1, 5.4] vs 1.4 [0, 4.9] pg/ml), p = .013), hsCRP (NP: 5.2 (1.5-7.1)
vs 0.9 (0.6-2.1) mg/l, p = .001), and sCD40L (NP: 10.53 [5.87, 14.43] vs 0 [0, 4.1] ng/ml,
p = .001) were significantly higher in sedentary controls compared to A. Changes of
inflammatory markers were not significantly different between subgroups with CVR and
CHD. Controls showed worse levels of HDL cholesterol (p = .004) and triglycerides (p =
.012) and smoked more often (χ2, p = .008). The use of aspirin, statins, ACE-inhibitors
and ARBs did not differ (χ2, n.s.).
Conclusion: An endurance training of 12 weeks decreased circulating chemotactic fac-
tors, which could lead to a more stable composition of atherosclerotic plaques by reduc-
ing inflammatory cells. Reduced sCD40L, IL-6 and hsCRP levels in physically active men
are rather caused by general and long-lasting life-style modification.
1165-106 Outpatient Clinic Base Therapeutic Program of Exercise 
After Heparin Administration for Patients With 
Arteriosclerosis Obliterans
Takanori Yasu, Taishi Hirahara, Yasuhiro Maejima, Hiroto Ueba, Nahoko Ikeda, Akihiro 
Kakehashi, Masatoshi Kuroki, Masanobu Kawakami, Muneyasu Saito, Omiya Medical 
Center, Jichi Medical School, Saitama, Japan
OBJECTIVES: We did a prospective study to examine a hypothesis that exercise pro-
gram combined with heparin administration improves clinical symptoms of patients with
arteriosclerosis obliterans (ASO) compared with exercise only in out-patient-clinic base.
METHODS: Consecutive 18 patients with symptomatic “no option” (inoperable) ASO
(Fontaine grade 2-3) diagnosed by angiography were randomly assigned to two groups;
a group of heparin and exercise (walking for 60 min after intravenous injection of 3,000
units of heparin three days a week for three months, n=9) and a group of exercise only
(n=9). Ankle brachial pressure index (ABI) and Treadmill exercise test (2.5 km/h, 10%
slope) were done before, 2 weeks, 12 weeks, and 24 weeks after the beginning of treat-
ment. Ophthalmic examinations including visual acuity test, ocular fundoscopy and fluo-
rescein angiographic fundus photography, and digital subtraction angiography of lower
extremities, and assessment of quality of life using SF36 score were repeated before and
24 weeks after the start of program.
RESULTS: Maximum walking time significantly increased in the group of exercise and
heparin compared with the group of exercise both at 12 weeks and 24 weeks. There was
no significant differences in ABI between two groups through the study period. Although
only two out of seven patients (22%) showed increased collateral flow in the group of
exercise at 24 weeks, five patients (56%) showed increased collateral vessel flow in the
group exercise and heparin. There were no patients who showed pathological retinal
angiogenesis.
CONCLUSION: Exercise program combined with heparin administration improves clini-
cal symptoms of ASO partly via accelerating angiogenesis without exacerbation of dia-
betic retinopathy.
1165-107 Measurement Versus Calculation of Training Heart Rate 
in Patients With Coronary Artery Disease Treated by 
Beta-Blockers
Philippe Meurin, Ahmed Bendriss, Helene Weber, Gabriel Thabut, Benedicte Zamblera, 
Dominique Odjinkem, Nathalie Renaud, Jean Yves Tabet, Les Grands Pres, Villeneuve 
Saint Denis, France
Background : In patients with coronary artery disease, target intensity-level of exercise
training is usually adjusted by a training heart rate (THR) which aims to be closed to the
anaerobic threshold heart rate.
THR should be measured during an exercise test with gas analysis but it is usually calcu-
lated from the Karvonen “formula” after a conventional exercise test : THRc = 0.6x(MHR-
RHR) + RHR; THRc = calculated Training Heart Rate, MHR = Maximal Heart Rate,
RHR=Resting Heart Rate. However this “formula” was only assessed in 6 normal sub-
jects.
The aim of this study is to evaluate whether a THR calculation after a regular exercise
test is reliable in patients treated with beta-blockers.
Methods : Multicentric prospective study; Patients underwent an exercise test with gas
analysis (with a ramp protocol, 10w/min) HR at the anaerobic threshold was measured
(THRm : measured Training Heart Rate) and was compared to THRc .
Results: 86 consecutive patients 56 + 20 years old were included, 20 + 5 days after an
acute myocardial infarction. All were treated with beta blockers. Left ventricular ejection
fraction was 48 + 5%.
Patients heart rate measured at AT (Mean THRm = 102 + 18 bpm) was significantly
greater than THRc (91 + 15 bpm; p = 0.0008).
THRm was more than 10 % above THRc in 50 % of the patients (patients undertrained if
the Karvonen formula is used ; fig 1);
Using a “Karvonen modified formula” : THR = 0.9x(MHR-RHR) + RHR allows calculating
a HR closer to the THRm (r = 0.91, p<0.0001)
Conclusion
Using The Karvonen “formula” in betablockers treated patients may lead to undertrain
patients after MI; this “formula” should be adapted in these patients to predict more accu-
rately heart rate at the anaerobic threshold.
1165-108 Prevalence and Effects of Cardiac Rehabilitation on 
Hostility in Young Coronary Patients
Carl J. Lavie, Richard V. Milani, Gail Brewer, Ochsner Clinic Foundation, New Orleans, 
LA
Background: We and others have published studies indicating that hostility is a significant
CAD risk factor and adversely affects recovery after major CAD events. However, no data
exists on the prevalence of hostility in various subgroups of CAD patients or on the
effects of cardiac rehabilitation and exercise training (CR/ET) on them.
Methods: Using the Kellner Symptom Questionnaire, a validated measure to assess vari-
ous behavioral characteristics, and the MOS-SF36 to assess quality of life (QoL), we
studied 81 young CAD patients (<50 years; 45 ± 5 years) and 268 elderly (>= 65 years;
70 ± 4 years) for hostility scores, prevalence of high hostility (HH; symptom score > 7
units), other CAD risk factors, and response to Phase II CR/ET programs.
Results: Hostility scores were considerably higher in the young than in the elderly (5.6 ±
6.0 vs. 2.1 ± 3.2 units; p<0.01) and the prevalence of HH was 3.5 times higher in younger
patients (28% vs. 8%; p<0.01). Young with HH had higher total cholesterol (TC; 232 ± 55
vs. 195 ± 41 mg/dl; p<0.01), triglycerides (400 ± 501 vs. 179 ± 83 mg/dl; p<0.01), TC/
HDL ratio (7.5 ± 3.6 vs. 5.9 ± 1.7; p<0.01), fasting glucose (141 ± 70 vs. 104 ± 21 mg/dl;
p<0.001), glycosylated hemoglobin (6.4 ± 2.0 vs. 5.6 ± 0.9%; p=0.03), and lower QoL (88
± 13 vs. 103 ± 16 units; p<0.001) compared with young with low hostility. Following CR/
ET, young with HH had marked improvements in TC (-15%; p<0.01), triglycerides (-53%;
p<0.01), TC/HDL (-23%; p<0.001), hostility score (-43%; p<0.01), and QoL (+26%;
p<0.0001), as well as improvements in other CAD risk factors. Compared with young with
LH, those with HH have significantly greater improvements in TC (p<0.01), body mass
indices (p<0.05), hostility score (p=0.03), and QoL (p<0.01) following CR/ET.
Conclusion: Young coronary patients have a high prevalence of high hostility and these
patients have quite adverse CAD profiles compared with other patients. Greater empha-
sis is needed on reducing hostility and other parameters of psychological distress in
young CAD patients as well as the potential benefits of CR/ET in the secondary preven-
tion of CAD.
